Pharma & Biotech Mergers & Acquisitions News
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Pharmaceutical
Swiss pharma giant Novartis today announced an upgrade to its mid-term guidance, in advance of its Meet Novartis Management event for investors and analysts in London. 21 November 2024
Biotechnology
Aizen Therapeutics, an AI-driven biotech headquartered in San Diego, has officially launched from stealth mode, introducing its drug discovery platform, DaX. 21 November 2024
Biotechnology
Massachusetts, USA-based firm VBI Vaccines has initiated a nationwide voluntary recall of PreHevbrio (hepatitis B vaccine), as it proceeds with bankruptcy and the shutdown of its operations. 19 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Biotechnology
Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which benefited Bristol Myers Squibb. Also on the research front, Germany’s Merck KGaA and Abbisko’s pimicotinib showed positive results in tenosynovial giant cell tumor (TGCT). M&A news saw German BioNTech punting $800 million upfront to acquire China based oncology focused Biotheus. Also of note, US drugmaker Halozyme Therapeutics made an unsolicited takeover bid for Evotec, valuing the German firm, at around 2 billion euros. 17 November 2024
Biosimilars
South Korean biosimilars company Celltrion today announced its acquisition of iQone Healthcare Switzerland a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland. 15 November 2024
Biotechnology
Shares of German drug discovery company Evotec leapt 20% to 10.33 euros this morning on the revelation that the USA’s Halozyme Therapeutics has submitted a non-binding proposal to acquire Evotec for 11.00 euros per share in cash, implying a fully-diluted equity value of around 2.0 billion euros ($2.12 billion). 15 November 2024
Biotechnology
BeiGene has announced plans to rebrand as BeOne Medicines, a move the cancer specialist says reflects its commitment to fighting cancer through collaboration. 15 November 2024
Pharmaceutical
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
Biotechnology
Although it is seeing a downturn in sales and profits, German biotech BioNTech is continuing to acquire assets with the cash pile it made through the covid pandemic, notably iis Comirnaty vaccine that was developed with Pfizer (NYSE: PFE). 13 November 2024
Biotechnology
Trace Neuroscience, a newly launched biopharma based in San Francisco, aims to advance treatments for neurodegenerative diseases, starting with amyotrophic lateral sclerosis (ALS). 12 November 2024
Biotechnology
AlloVir has entered into a definitive agreement to merge with biopharma company Kalaris Therapeutics. 8 November 2024
Pharmaceutical
European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024
Biotechnology
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
Pharmaceutical
Pharmaceutical M&A came back with a bang during October, after a quiet September. 5 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Biotechnology
Maryland, USA–based glycobiology specialist GlycoMimetics has entered into an acquisition agreement with Crescent Biopharma, a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. 30 October 2024
Biotechnology
German drugmaker Dr Falk Pharma GmbH today announced completion of the acquisition of Kynos Therapeutics, a clinical stage biopharmaceutical company focusing on the development of novel KMO inhibitors for acute and chronic inflammatory diseases. 29 October 2024
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Biotechnology
Ottimo Pharma, a biotech founded by Medicxi in 2020, has emerged from stealth mode with an executive team packed with prominent industry leaders. 28 October 2024
Pharmaceutical
Spain’s leading drugmaker Almirall discussed its strategy with The Pharma Letter’s local correspondent, explaining why it has moved out of the respiratory sector to focus on dermatology. 23 February 2016
Generics
The US Federal Trade Commission was seen to flex its muscles on Friday, as it imposed conditions on two proposed M&A deals. 21 February 2016
Pharmaceutical
Mergers and acquisition news during the past week has had a negative impact on the share prices of the buyers. 13 February 2016
Pharmaceutical
Mylan has announced a public offer to shareholders of Sweden’s Meda to acquire all the shares of the company, in a deal worth a total of $7.2 billion ($9.9 billion including debt. 11 February 2016
Generics
Following receipt of new financial performance information from Boehringer Ingelheim, Jordon-based drugmaker Hikma Pharmaceuticals said today that is revising the terms of the acquisition of the family-owned German pharma major’s Roxane Laboratories unit. 10 February 2016
Pharmaceutical
By Barbara Obstoj-Cardwell - Editor
Gilead Sciences came up with a good set of financials late Wednesday, beating expectations, particularly with its new hepatitis C drugs, Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir), with the latter generating sales of $3.35 billion in the fourth quarter of 2015, beating expectations of $3.1 billion. 6 February 2016
Biotechnology
China-based Sinovac Biotech, which earlier this week revealed a takeover approach from SAIF Partners, today announced that it has received an alternative offer to acquire the company. 4 February 2016
Biotechnology
US contract research and manufacturing organization ABL Inc, through its wholly-owned subsidiary ABL Europe, has acquired Transgene’s production asset situated in Illkirch, near Strasbourg. 4 February 2016
Pharmaceutical
(January) - The year 2015 saw hectic merger and acquisition activity as the companies took to expanding the bottom lines via the takeover route. The sluggishness in the global economy has meant the profits have stagnated and the one way to bolster margins is the through M&A’s. 3 February 2016
Pharmaceutical
In our weekly expert view piece, Joe Stelzer, managing partner at Cavendish Corporate Finance LLP, examines the emerging ‘research by acquisition’ model in big pharma. 2 February 2016
Pharmaceutical
Drugmaker Abbott has entered into a definitive agreement for to acquire fellow USA-based Alere, significantly advancing Abbott's global diagnostics presence and leadership. 1 February 2016
Pharmaceutical
Almirall says it has exercised a call option to acquire 100% of the share capital of ThermiGen, a privately held USA-based medical aesthetics technology company and a developer and manufacturer of thermistor-regulated energy systems for plastic surgery and aesthetics dermatology applications. 1 February 2016
Generics
Gedeon Richter says it has acquired from its partner, Rxmidas Pharmaceuticals Holdings, its outstanding 50% stake in Gedeon Richter Rxmidas Joint Venture Co Ltd following the setting up of a joint venture with an initial 50% share of equity announced in December 2010. 1 February 2016
Pharmaceutical
Trillium Therapeutics has acquired all of the outstanding shares of fellow Canada-based privately-held Fluorinov Pharma, an independent business trust FACIT portfolio company, in a deal worth up to C$45 million ($32 million). 28 January 2016
Biotechnology
Finland’s Biotie Therapies saw its shares rocket 88% to 0.28 euros in early trading, after US biotech Acorda Therapeutics announced it has reached agreement to acquire the company. 19 January 2016
Biotechnology
UK biotech firm Centauri Therapeutics said today it has acquired the Alphamer technology for drug discovery and development from Altermune Technologies. 18 January 2016
Pharmaceutical
Swedish mitochondrial medicine firm NeuroVive Pharmaceutical has made a partial acquisition of UK-based Isomerase Therapeutics, with the overall goal to strengthen the partnership and accelerate its R&D program. 16 January 2016
Biotechnology
DNAmito said it has acquired ptTheragnostic in Maastricht, Netherlands. PTT is a spin-off from the Maastricht University, University Medical Center and Maastro Clinic. 13 January 2016
Pharmaceutical
Merck & Co says it has acquired IOmet Pharma, a privately-held Scotland-based drug discovery company focused on the development of innovative medicines for the treatment of cancer. 12 January 2016
Biotechnology
US biopharma company Juno Therapeutics revealed yesterday that it has acquired AbVitro, a privately held biotechnology company based in Boston, Massachusetts. 12 January 2016
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze